Finance

Chemokine/cytokine-focused company announces exercise of over-allotment option

Published in Blood Weekly, March 3rd, 2005

Chemokine Therapeutics Corp. (CTI) announced that the underwriters of its recent initial public offering have exercised in full their over-allotment option and purchased an additional 2,400,000 common shares at the initial public offering price of CDN$1.00 per share.

All of the over-allotment shares were sold by the company. After giving effect to the sale of the over-allotment shares, a total of 18,400,000 common shares were offered and sold by the company in the initial public offering for gross proceeds to the company of CDN$18,400,000.

A syndicate of investment dealers led by Canaccord Capital Corp. and including Jennings Capital, Inc., McFarlane...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-03-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry